FDA and EMA Join Forces on Botanical Drug Development

A joint FDA/EMA workshop on September 25, 2026 signals that regulators on both sides of the Atlantic are moving toward coordinated expectations for botanical drug products, a category where only four approvals exist under NDA and BLA pathways, yet sponsor interest continues to grow. For plant heads and QA directors preparing to enter this space, the convergence of two major agencies around shared standards is the operative development.

Botanical drug products present characterization and quality control challenges that distinguish them from conventional small molecules. Their inherent biological variability, spanning plant materials, algae, macroscopic fungi, and combinations thereof, complicates batch consistency, identity testing, and process validation under 21 CFR Part 211. FDA's 2016 guidance addressed these dimensions, but the agency's current activity suggests that guidance alone has not resolved the development bottlenecks sponsors face.

The four approved products offer a narrow but instructive reference set. The three NDAs cover sinecatechins, crofelemer, and birch triterpenes; the single BLA covers anacaulase-bcdb. Each approval represents a distinct characterization strategy, and QA leads building comparability frameworks or analytical method packages for new botanical INDs should treat these precedents as the closest available benchmarks for regulatory expectations around sterility assurance and specification-setting.

Alongside the workshop, FDA has issued a Request for Information seeking stakeholder perspectives on the current state of botanical drug development in the United States, and convened a roundtable with the Reagan-Udall Foundation to surface specific development challenges. The parallel tracks, agency-to-agency harmonization and agency-to-industry dialogue, indicate that FDA is building a more structured regulatory posture for this category rather than handling submissions on a purely case-by-case basis.

Regulatory affairs leads monitoring ICH Q10-aligned quality system requirements should note that the EMA's involvement introduces the prospect of aligned dossier expectations, which would affect both Module 3 content strategy and post-approval change management protocols for sponsors seeking simultaneous US and EU market access.

The September 25 workshop registration deadline and the open Federal Register comment period represent concrete near-term checkpoints for organizations tracking how FDA and EMA will define acceptable characterization standards for botanical active ingredients entering the prescription drug pipeline.

Source: FDA Drugs RSS Feed via fda.gov, September 3, 2026. Joint FDA/EMA workshop scheduled September 25, 2026; registration open.